A Phase II Study to Evaluate the Efficacy and Safety of GT90001 in Combination with Nivolumab as a Second-line Treatment in Subjects with Advanced Hepatocellular Carcinoma

Brief description of study

The purpose of the study is to examine and assess the antitumor activities of Nivolumab in combination with GT90001 or Nivolumab alone in subjects with advanced hepatocellular carcinoma (aHCC) who had progressed after or intolerant to first-line treatment. We want to evaluate the efficacy of GT90001 in combination with Nivolumab compared with Nivolumab in patients with advanced Hepatocellular Carcinoma (aHCC) who had progressed after or intolerant to first-line treatment with a tyrosine kinase inhibitor. We also want to evaluate the efficacy of GT90001 in combination with Nivolumab in patients with aHCC who had progressed after or intolerant to first-line treatment of Atezolizumab combined with Bevacizumab. The study drug and combination are investigational, which means that the study drug and combination have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this combination in the current trial.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.